61 related articles for article (PubMed ID: 20514061)
1. Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment.
Nat Rev Drug Discov; 2010 Jun; 9(6):423. PubMed ID: 20514061
[No Abstract] [Full Text] [Related]
2. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery.
Printz C
Cancer; 2010 Jul; 116(14):3307-8. PubMed ID: 20602437
[No Abstract] [Full Text] [Related]
3. Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):244-5. PubMed ID: 12113042
[No Abstract] [Full Text] [Related]
4. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.
Zalcman G; Bergot E; Creveuil C; Levallet G; Lechapt E
Curr Opin Oncol; 2011 Jan; 23(1):106-11. PubMed ID: 21076302
[TBL] [Abstract][Full Text] [Related]
5. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
6. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices.
Shepherd FA
J Clin Oncol; 2000 Nov; 18(21 Suppl):35S-8S. PubMed ID: 11060323
[No Abstract] [Full Text] [Related]
8. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
Crawford J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
[TBL] [Abstract][Full Text] [Related]
9. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
Freidlin B; Breathnach OS; Johnson BE
Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trials in patients with lung cancer].
Shinkai T; Saijo N
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():232-44. PubMed ID: 8007470
[TBL] [Abstract][Full Text] [Related]
11. [Combination assay of tumor markers in predicting the effectiveness of chemotherapy in non-small lung cancer].
Satoh H; Yano H; Suyama T; Hasegawa S
Gan To Kagaku Ryoho; 1992 Jan; 19(1):127-9. PubMed ID: 1346084
[No Abstract] [Full Text] [Related]
12. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
13. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
[TBL] [Abstract][Full Text] [Related]
14. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride D
ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
[No Abstract] [Full Text] [Related]
15. "Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial".
Holoye PY
Cancer Treat Rep; 1987 Apr; 71(4):431-2. PubMed ID: 3030548
[No Abstract] [Full Text] [Related]
16. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
17. [Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years].
Santo A; Genestreti G; Fiorio E; Terzi A; Lonardoni A; Calabrò F; Campaldini B; Colaluca P; Molino A; Cetto GL
Recenti Prog Med; 2006 Apr; 97(4):211-8. PubMed ID: 16729492
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer.
Edelman MJ
Expert Rev Anticancer Ther; 2001 Aug; 1(2):229-35. PubMed ID: 12113028
[TBL] [Abstract][Full Text] [Related]
19. An overview of the design and conduct of the BATTLE trials.
Liu S; Lee JJ
Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
[TBL] [Abstract][Full Text] [Related]
20. [What we can learn from a case of medical malpractice--physician's violation of duty of care and error in clinical judgment regarding study eligibility denied as the cause of patient's death one month following study drug administration].
Kajitani A; Asada M; Kuwabara H; Kawasaki S; Kobayashi H
Nihon Geka Gakkai Zasshi; 2014 Jan; 115(1):39-40. PubMed ID: 24597337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
